Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.
No big deals needed, executives insist, but a pipeline purge continues and analysts warn of a growth problem.
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Sangamo emulates Editas, while Crispr/Vertex and Bluebird add weight to their ambitions.
The company insists its $80m tie-up with Metagenomi will not lead to a loss of focus.